Nurix Therapeutics (NRIX) Income towards Parent Company: 2019-2025
Historic Income towards Parent Company for Nurix Therapeutics (NRIX) over the last 6 years, with Aug 2025 value amounting to -$86.4 million.
- Nurix Therapeutics' Income towards Parent Company fell 76.53% to -$86.4 million in Q3 2025 from the same period last year, while for Aug 2025 it was -$244.8 million, marking a year-over-year decrease of 38.32%. This contributed to the annual value of -$193.6 million for FY2024, which is 34.47% down from last year.
- According to the latest figures from Q3 2025, Nurix Therapeutics' Income towards Parent Company is -$86.4 million, which was down 98.83% from -$43.5 million recorded in Q2 2025.
- Over the past 5 years, Nurix Therapeutics' Income towards Parent Company peaked at -$24.3 million during Q1 2021, and registered a low of -$86.4 million during Q3 2025.
- Over the past 3 years, Nurix Therapeutics' median Income towards Parent Company value was -$43.5 million (recorded in 2025), while the average stood at -$47.6 million.
- Its Income towards Parent Company has fluctuated over the past 5 years, first slumped by 448.05% in 2021, then skyrocketed by 46.53% in 2023.
- Over the past 5 years, Nurix Therapeutics' Income towards Parent Company (Quarterly) stood at -$37.7 million in 2021, then declined by 23.95% to -$46.7 million in 2022, then climbed by 10.19% to -$42.0 million in 2023, then plummeted by 39.55% to -$58.5 million in 2024, then tumbled by 76.53% to -$86.4 million in 2025.
- Its last three reported values are -$86.4 million in Q3 2025, -$43.5 million for Q2 2025, and -$56.4 million during Q1 2025.